As expected, Celgene Corp. finished its rolling new drug application for Revlimid, asking for the FDA's approval based on Phase II data with the compound for myelodysplastic syndromes (MDS) in transfusion-dependent patients with a 5q-deletion chromosomal abnormality. (BioWorld Today)